TCGA-LL-A7SZ-01A-32R-A352-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 20
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.450
- ALLOGRAFT_REJECTION+0.420
- OXIDATIVE_PHOSPHORYLATION+0.390
- XENOBIOTIC_METABOLISM+0.320
- DNA_REPAIR+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- KRAS_SIGNALING_DN+0.280
- MYOGENESIS+0.210
- COAGULATION+0.200
- ESTROGEN_RESPONSE_LATE+0.190
Top 10 suppressed
- UV_RESPONSE_DN-0.520
- PROTEIN_SECRETION-0.470
- TGF_BETA_SIGNALING-0.470
- MITOTIC_SPINDLE-0.420
- HEDGEHOG_SIGNALING-0.390
- NOTCH_SIGNALING-0.340
- TNFA_SIGNALING_VIA_NFKB-0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- APICAL_JUNCTION-0.230
- WNT_BETA_CATENIN_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a8cd01e2-f7f4-487c-8cde-4fcf21bfe0e7 | — | — | 0.790 |
| 2 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.768 |
| 3 | SRR11296848 | — | — | 0.758 |
| 4 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.754 |
| 5 | TCGA-37-4130-01A-01R-1100-07 | — | cohortA1 | 0.753 |
| 6 | TCGA-GM-A2DB-01A-31R-A18M-07 | — | C | 0.751 |
| 7 | TCGA-49-4506-01A-01R-1206-07 | — | cohortA4 | 0.750 |
| 8 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.748 |
| 9 | TCGA-LL-A5YM-01A-11R-A28M-07 | — | B | 0.746 |
| 10 | TCGA-A7-A6VW-01A-21R-A33J-07 | — | E | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.320 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |